Issue |
J Oral Med Oral Surg
Volume 30, Number 3, 2024
|
|
---|---|---|
Article Number | 38 | |
Number of page(s) | 5 | |
DOI | https://doi.org/10.1051/mbcb/2024041 | |
Published online | 31 January 2025 |
Case Report
Maxillary osteonecrosis linked to Pembrolizumab therapy: a case report
1
Service d'odontologie CHU de Rouen, Rouen, France
2
Service d'odontologie CHU de Créteil, Créteil, France
3
Service d'odontologie CH du Havre, Le Havre, France
* Correspondence: l.gosselinr@gmail.com
Received:
29
August
2024
Accepted:
29
November
2024
Introduction: Osteonecrosis of the jaw is a serious condition often associated with the use of bone-modifying agents or antiangiogenics. Recent evidence suggests that immune checkpoint inhibitors, including Pembrolizumab, might also contribute to osteonecrosis of the jaw. Observation: An 83-year-old male with metastatic non-small cell lung cancer treated exclusively with Pembrolizumab developed osteonecrosis of the maxilla. Management included sequestrectomy, curettage, placement of Platelet-rich-Fibrin (PRF) and antibiotics. Despite initial improvement, symptoms recurred. The patient eventually stabilized but passed away a few months later. Discussion: A literature review was conducted supporting the hypothesis that the mechanism may involve disrupted bone remodeling due to enhanced immune activity. This highlights the need for further research to clarify the potential association between Pembrolizumab and osteonecrosis, and to develop preventive and management strategies. Conclusion: While definitive causality between Pembrolizumab and osteonecrosis of the jaw cannot be established with the current evidence, this case adds to the growing body of literature suggesting that immune checkpoint inhibitors may be implicated in the pathogenesis of osteonecrosis of the jaw. As the use of immunotherapy expands in oncology, further research is essential to elucidate this association and provide guidelines.
Key words: Pembrolizumab / osteonecrosis / maxilla
© The authors, 2025
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.